DeepX Diagnostics Inc.’s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions

DeepX Diagnostics Inc. announced that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration for teledermatology screening of suspect skin cancer lesions in the United States.

Scroll to Top